7-[2-[4-(6-fluoro-3-methyl-1,2-benzisoxazol-5-yl)-1-piperazinyl]ethyl]-2-(1-propynyl)-7H-pyrazolo-[4,3-E]-[1,2,4]-triazolo-[1,5-C]-pyrimidin-5-amine
The compound having the structural formula I or a pharmaceutically acceptable salt thereof, is disclosed, as well as its use in the treatment of central nervous system diseases, in particular Parkinson's disease, Extra Pyramidal Syndrome, restless legs syndrome and attention deficit hyperactivity disorder, pharmaceutical compositions comprising it, and combinations with other agents.
1. A compound having the structural formula
or a pharmaceutically acceptable salt thereof.
2. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 in a pharmaceutically acceptable carrier.
3. A pharmaceutical composition comprising a therapeutically effective amount of a combination of the compound of claim 1 , and 1 to 3 other agents useful in treating Parkinson's disease in a pharmaceutically acceptable carrier.
4. The composition of claim 3 wherein said other agents are independently L-DOPA, dopaminergic agonists, MAO-B inhibitors, DOPA decarboxylase inhibitors or COMT inhibitors.